ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54 | -44.9% | 10,259 | 0.0% | 0.00% | – |
| Q2 2023 | $98 | -14.8% | 10,259 | -2.5% | 0.00% | – |
| Q1 2023 | $115 | -23.8% | 10,519 | +2.5% | 0.00% | – |
| Q4 2022 | $151 | -99.9% | 10,259 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $196,000 | -10.1% | 10,259 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $218,000 | +10.7% | 10,259 | 0.0% | 0.00% | – |
| Q1 2022 | $197,000 | -7.1% | 10,259 | 0.0% | 0.00% | – |
| Q4 2021 | $212,000 | -13.5% | 10,259 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $245,000 | -12.8% | 10,259 | -0.5% | 0.00% | 0.0% |
| Q2 2021 | $281,000 | -11.6% | 10,309 | -6.2% | 0.00% | 0.0% |
| Q1 2021 | $318,000 | – | 10,994 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |